MRX-2843 is under clinical development by Meryx and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MRX-2843’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRX-2843 is under development for the treatment of relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, solid tumors including melanoma, breast cancer, glioblastoma and non-small cell lung cancer. It is administered orally as a tablet and capsule. The drug candidate is a bi-specific antibody which acts by targeting of Mer tyrosine kinase and Fms-like tyrosine kinase 3 (FLT3).
Meryx., a developer of mer tyrosine kinase inhibitor therapeutics for cancer. The company is headquartered in United States.
For a complete picture of MRX-2843’s drug-specific PTSR and LoA scores, buy the report here.